As a physician-scientist, the focus of my interest is translational research directly targeting hematologic disease. My immediate goals are to systematically clarify the molecular mechanisms of myeloid diseases and ultimately improve management of these conditions. As such, academic research is the best pathway to achieving these goals.

Julien Mancini (MD, PhD) is a Professor of Public Health, head of the “Cancer, Biomedicine & Society” research group (UMR1252 SESSTIM, Aix-Marseille Univ, Inserm, IRD, ISSPAM) and affiliated to the Clinical Epidemiology & Biostatistics unit at the Timone Hospital (Marseille, APHM). He received a master’s degree in epidemiology from Paris University in 2004, a medical degree from Aix-Marseille University in 2006, and a Ph.D. degree in oncology from Aix-Marseille University in 2008. His main research interests include health literacy, risk communication and patients’ involvement in decision-making, especially about participating in innovative cancer care (clinical trials, genetic testing, etc.). He develops mainly mixed-methods studies with the help of researchers (anthropologist, economists, sociologist, etc.) from his multidisciplinary group.

Klaus is Professor of Translational Hematology at the University of Leipzig, Germany. He is a clinician-scientist interested in genomic prognostic and predictive biomarkers in myeloid diseases. His lab is also working on clonal hematopoiesis and its relation to hematologic and non-hematologic diseases. He obtained his MD degree at Technical University of Munich, and trained as a hematologist at LMU Munich.

Moshe Mittelman MD, completed his term as the Chairman, Department of Medicine, at the Tel Aviv Sourasky (Ichilov) Medical Center, in 2020. Currently, he continues as a senior consultant for Hematology. He is also Professor Emeritus, in medicine and hematology, the Sackler School of Medicine, Tel Aviv University. Among other tasks, Prof. Mittelman serves as the Chief Technology Officer, Scientific-Medical Director and a consultant for a biotech fund (TALENT) and investors, and is involved in several biotech start-ups companies. In 2019 he established, and continues to run a hematologyoncology service in the LISOD Oncology Center, in Kiev, Ukraine. Professor Mittelman graduated from the Sackler School of Medicine in 1976, and completed a Residency in Internal Medicine at the Hasharon Hospital, Petah-Tikva, Israel. He later undertook a Combined Clinical and Research Fellowship Programme in Hematology and Oncology at the George Washington University Medical Center, Washington DC, USA, and The National Institutes of Health (NIH), Bethesda, USA, before returning to Israel in 1989. On returning to Israel, he served as Deputy-Director (1989-1994) and then Director (1994-2003), Department of Medicine B, Hasharon Hospital. In 2003 he moved to Ichilov Medical Center, to serve as the Chief of Medicine A and the Chairman of The Department of Medicine (9 wards, 360 beds), till 2020. Professor Mittelman’s research interests include basic and clinical aspects of stem cell disorders such as myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), multiple myeloma, basic and clinical effects of erythropoietin, translational research of malignant hematology and applying digitalization into practical medicine. He published more than 200 professional papers summarizing his clinical and research activities in prestigious journals such as Blood; Haematologica; British Journal of Haematology; American Journal of Hematology; Annals of Hematology; Leukemia Research; Annals of Internal Medicine; and others. He was a member of the editorial board of European Journal of Internal Medicine, and currently serves in the editorial board of the Israel Medical Association Journal (IMAJ) and Haematologica, as well as a reviewer for the top journals in hematology, oncology and medicine. Over the years Moshe has served in academic and public duties, including Chairman, the admission committee for medical students, TAU; The National Committee for new technologies in public health ("Vaadat Sal"); BOD, Israel Cancer Association (he is currently the Acting Chairman of the Association, Aguda); Board of Trustees, The Academic College Tel Aviv-Jaffa; Secretary & Chairman, Israel Society of Internal Medicine; President, Israel Society of Hematology; The national committee for clinical trials (Helsinki), Israel Ministry of Health; and Chairman, the Scientific Board, International MDS Foundation.